Nanobiotechnology - Global Strategic Business Report

  • ID: 344092
  • Report
  • Region: Global
  • 267 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Ablynx NV (Belgium)
  • Celgene Corporation (USA)
  • ELITechGroup (France)
  • GlaxoSmithKline Plc. (UK)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • MORE
The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 79 companies including many key and niche players such as:
  • Ablynx NV
  • Arrowhead Pharmaceuticals, Inc.
  • Avadel Pharmaceuticals plc
  • CaPtivate Pharmaceuticals LLC
  • Celgene Corporation
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ablynx NV (Belgium)
  • Celgene Corporation (USA)
  • ELITechGroup (France)
  • GlaxoSmithKline Plc. (UK)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • MORE

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
A Curtain Raiser
Nanobiotechnology
The Next Big Thing
An Insight into the Global Nanobiotechnology Market
Major Market Drivers
Where Conventional Molecular Science Falls Short Nanobio Steps In
Nanotechnology Revolutionizes Pharmaceuticals & Healthcare Sector
Nanomedicine Market to Achieve Phenomenal Growth
Opportunities Galore for Nanomedicine
Drug Delivery
A Promising Application Area for Nanotechnology
Nanotechnology Offers Huge Potential in Brain Disorder Treatment
High Demand for Nanobots and Nano Healthcare Devices
Nanotechnology Gaining Prominence for Treatment of Cancer
Nanotechnology in Drug Delivery: A Specialized Market Opportunity
Commercialization of Nanotechnology-based Medical Products Gains Momentum
Nanodiagnostic Products to Witness Strong Demand Growth
Dendrimers Serve as a Base to Build Multifunctional Nanodevices
Nanotechnology Rescues Poor Water Soluble Drugs from Abandonment
Huge Opportunities for Nanomaterials in the Medical Field
Commercial Opportunities in Healthcare Sector
Future Possibilities
Global Market for Fullerenes
An Insight
Dawn Breaks on Nanobiotechnology
Demystifying the Intriguing World of Nanobiotech
A Meeting Place of Medicine’s Best Solutions
Nanobiotechnology to Become Viable for All Drug Development Stages
Nanoparticles: The Foundation of Nanobiotechnology
Improved Optical Properties and Stability of Nanoparticles
Nanoemulsions
The Promise of Nanobiotechnology
Biological Weaponries against Diseases Come in Small Packages
Proffered Benefits of Nanobiotechnology
Opportunity & Beyond
Nanobiotechnology
Will it Live Up to the Expectations?
The Future of Nanobiotechnology: Shape of Things to Come
Nanobiotechnology: The Outer Limits
Futuristics: A Rumination
Conclusions

2. COMPETITIVE SCENARIO
Competition in Select Segments
Nanoparticles
Nanotubes and Fullerenes
Dendrimers
Small and Medium-Sized Enterprises Spearheading Product Development
List of Select Approved Nanotechnology-based Drug Delivery Devices
Status of Select Nanoscale Drug Delivery Devices
Collaborations Activity Picking Up Pace in Nanomedicine Domain

3. MARKET DYNAMICS
Present Status and Future Opportunities
Outlook
Developing Countries to Rise over the Horizon
Nanomaterials & Nanoparticles Witness Robust Activity
Focus on Improved Performance to Bring New Manufacturing Methods for Nanomaterials
Why Invest in Nanobiotechnology?
Private and Public Companies to Step Up Funding on Nanotechnology
United States Lead the Way in Government Funding
Increasing Awareness on Technology to Drive Growth
Demand for Novel Products to Push Up Growth
Nano-Enabled Drug Discovery Holds Tremendous Potential
Consolidation Sharpens the Industry’s Edge
The Regulatory Framework Evolves with the Technology
Quantum Dot Patents Pose Legal Tangles
Miniaturized Liquid Handling Becomes Progressive
Trends in Nanotechnology Enabled Drug Delivery Systems
Patent Expiries: A Key Driver
Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs

4. INDUSTRY CHALLENGES & ISSUES
Challenges
Commercial Exploration: A Treacherous Voyage
Conventional Medicine to Contest Nanomedicine Adoption
Complexity of Nanotechnology Based Diagnostics and Treatment Methods Pose Challenges
Nanomaterials Use: Weighed Down with Toxicity Concerns
Production Issues Continue to Plague Nanobiotech Industry
Lack of De Facto Standards: A Challenge to Reckon With
Embroilment over Ethical Issues
Social Relevance
Economic Relevance

5. INDUSTRY STRUCTURE
Industry Structure: A Quick Primer
A Peek into the Regulatory Framework
United States
Europe
A Closer Look at Regional Nano Efforts
United States: Unraveling the Country’s Edge
Table 3: Nanotechnology Patents in United States Patent and Trademark Office by Leading Countries: 2014-2016 (Sep) (includes corresponding Graph/Chart)
Table 4: Nanotechnology Patents In European Patent Office by Leading Countries: 2014-2016 (Sep) (includes corresponding Graph/Chart)
Table 5: Leading Countries in Terms of Number of Research Publications for Nanopolymeric Cardiac Scaffolds: 2005-2015 (June) (includes corresponding Graph/Chart)
Europe: Hot on the Heels of the US
Japan: A Noteworthy Region

6. NANOBIO’S EPOCHAL STRIDES IN MODERN MEDICINE
A Primer
Impact on Drug Delivery Systems
Benefits Offered
Impact on Molecular Diagnostic Imaging
Seeing the Unseen
Impact on Therapeutics
Silver Nanoparticles as Effective Antimicrobial Agents
Modern Day Nanomedicine: A Current Scenario
Nanomedicine: The Cynosure of All Eyes
Nanotechnology Enabled Diagnostics
Conclusions
Gauging the Real World Impact of Nanobiotech on Cancer: A Case Study
Quantum Dots Cock a Snook at Traditional Anti-Body Labeling Agents
Chemotherapeutic Reengineering & Gene Therapy: New Treatment Regimes
Futuristic Applications
Bio-molecular Motors
Genetic and Tissue Engineering
Laboratory-on-chip (LOC): A Portable Diagnostic Laboratory
Medical Diagnostic Sensors
Nano Medical Devices
From Surgical Tools to Contact Lenses
Nanoengineered Prosthetics
Nanotubes
Potential Drug Delivery Vehicles

7. INNOVATIONS & ADVANCEMENTS
A*STAR Researchers Develop Nano-Sized Drug Molecules for Cancer Treatment
MIT Researchers Develop Nanodevice for Fighting Against Cancer Drug Resistance
Gold Nanotubes for Several Applications in the Fight Against Cancer
IBM Research Working on NanoDLD Technology for Early Diagnosis of Cancer and other Diseases
Antifungal Bionanocomposites for Medical Devices
DNA Nanostructures for Smart Diagnosis and Drug Delivery
Japanese Scientists Develop CNTs with Polymeric Coatings for Enhanced Drug Delivery
Other Noteworthy Nanotechnology Related Technology Innovations

8. CONCEPTUAL OVERVIEW

9. GLOBAL RESEARCH CENTERS AND INSTITUTIONS
Cornell's Nanobiotechnology Center (USA)
Institute of Bioengineering and Nanotechnology (Singapore)
Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS) (USA)
The Tyndall National Institute (Ireland)

10. RECENT INDUSTRY ACTIVITY
Vectura Group Inks Merger Agreement with Skyepharma
Flamel Technologies to Merge with Avadel Pharmaceuticals
Pfizer to Acquire BIND Therapeutics Assets
Janssen Sciences Ireland Enters into Collaboration with ViiV Healthcare
Tekna Holdings Canada Inks Agreement with National Research Council of Canada
Roche and BioMed X Sign a Collaboration Agreement
Ablynx Enters into Exclusive Research Collaboration with Genzyme
Pfizer Exercises Option to Develop and Commercialize Accurin
BIND Therapeutics Inks Joint Research and Development Agreement with Merck

11. FOCUS ON SELECT GLOBAL PLAYERS
Ablynx NV (Belgium)
Arrowhead Pharmaceuticals, Inc. (USA)
Avadel Pharmaceuticals plc (Ireland)
CaPtivate Pharmaceuticals LLC (USA)
Celgene Corporation (USA)
ELITechGroup (France)
GlaxoSmithKline Plc. (UK)
Johnson & Johnson (USA)
Merck & Co., Inc. (USA)
NanoBio® Corporation (USA)
Nanophase Technologies Corporation (USA)
pSivida Corp. (USA)
Sigma-Aldrich Corp. (USA)
Starpharma Holdings Ltd. (Australia)
Vectura Group plc (UK)

12. GLOBAL MARKET PERSPECTIVE
Table 6: World Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region
US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 7: World Historic Review for Nanobiotechnology by Geographic Region
US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 8: World 14-Year Perspective for Nanobiotechnology by Geographic Region
Percentage Breakdown of Revenues for US, Japan, Europe, and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
Industry Overview
Academic Research Lending Strength to Creation of Novel Nanobiotech Products
Table 9: Number of Drugs Approved by FDA: 2001-2016 ( includes corresponding Graph/Chart)
Public Sector Funding
Table 10: National Nanotechnology Initiative Budget in US$ Million by Agency (2015-2017) (includes corresponding Graph/Chart)
Connecticut
A Key Region with Focus on Nanomedicine
Patent Activity in Nanomedicine Domain
Major Nanobiotechnology Institutions and Centers
The Nanobiotechnology Center (NBTC)
Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS)
Centers of Cancer Nanotechnology Excellence (CCNEs)
Regulatory Environment
FDA’s Regulatory Approach to Nanotechnology Products
The Perils of Current Regulatory Status on Nanostructures
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 11: US Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: US Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

2. JAPAN
A.Market Analysis
Outlook
Table 13: R&D Expenditure in Japan (2015): Percentage Breakdown of Expenditure by Industrial Sector for Energy, Environmental S&T, ICTs, Life sciences, Materials, Nanotechnology, and Others (includes corresponding Graph/Chart)
Nanomedicines in Japan
An Overview
List of Select Nanomedicines Approved in Japan
Regulations on Nanomedicine in Japan
B.Market Analytics
Table 14: Japanese Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 15: Japanese Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

3. EUROPE
A.Market Analysis
The Rise of Nanobiotechnology in Europe
EU Gears Up for Clarity on Nanomedicine Regulations
Market Overview
Nano2Life Network
Public Sector Funding
Regulatory Environment
Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks
A Snapshot of Nanotherapeutic Products in the EU
List of Select Oral Nanotherapeutic Products
List of Select Nanotherapeutic Products for Parenteral Administration
List of Select Nanotherapeutic Products for Parenteral Administration in the EU
Focus on Select Markets
Germany
France
United Kingdom
Russia
Rest of Europe
Ireland
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 16: European Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 17: European Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

4. REST OF WORLD
A.Market Analysis
Public Sector Funding
Focus on Select Markets
Australia
China
India
South Korea
Taiwan
Iran
Strategic Corporate Development
Starpharma Holdings Ltd.
A Major Australian Player
B.Market Analytics
Table 18: Rest of World Recent Past, Current & Future Analysis for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 19: Rest of World Historic Review for Nanobiotechnology Market Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 79

  • The United States (49)
  • Canada (2)
  • Japan (1)
  • Europe (19)
    • France (2)
    • Germany (6)
    • The United Kingdom (4)
    • Rest of Europe (7)
  • Asia-Pacific (Excluding Japan) (5)
  • Middle East (3)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ablynx NV (Belgium)
  • Arrowhead Pharmaceuticals, Inc. (USA)
  • Avadel Pharmaceuticals plc (Ireland)
  • CaPtivate Pharmaceuticals LLC (USA)
  • Celgene Corporation (USA)
  • ELITechGroup (France)
  • GlaxoSmithKline Plc. (UK)
  • Johnson & Johnson (USA)
  • Merck & Co., Inc. (USA)
  • NanoBio® Corporation (USA)
  • Nanophase Technologies Corporation (USA)
  • pSivida Corp. (USA)
  • Sigma-Aldrich Corp. (USA)
  • Starpharma Holdings Ltd. (Australia)
  • Vectura Group plc (UK)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll